MELA, Flora
 Distribuzione geografica
Continente #
NA - Nord America 1.595
EU - Europa 382
AS - Asia 325
OC - Oceania 1
SA - Sud America 1
Totale 2.304
Nazione #
US - Stati Uniti d'America 1.574
CN - Cina 152
UA - Ucraina 110
SG - Singapore 92
DE - Germania 90
TR - Turchia 74
GB - Regno Unito 64
FI - Finlandia 44
IT - Italia 38
CA - Canada 20
SE - Svezia 19
FR - Francia 5
BE - Belgio 4
CZ - Repubblica Ceca 3
IN - India 3
HK - Hong Kong 2
LT - Lituania 2
AU - Australia 1
CL - Cile 1
CR - Costa Rica 1
IE - Irlanda 1
IR - Iran 1
KH - Cambogia 1
NL - Olanda 1
RO - Romania 1
Totale 2.304
Città #
Woodbridge 225
Fairfield 216
Chandler 123
Jacksonville 121
Houston 119
Ashburn 112
Wilmington 82
Singapore 80
Santa Clara 76
Seattle 75
Cambridge 66
Ann Arbor 48
Beijing 47
Izmir 46
Munich 33
Nanjing 30
Shanghai 24
Helsinki 23
Princeton 23
Ferrara 20
New York 20
San Diego 16
Boardman 15
Bremen 13
Mcallen 13
Hebei 12
Montréal 12
Shenyang 9
Washington 8
Los Angeles 6
Milan 6
Changsha 5
Mountain View 5
Brussels 4
Jiaxing 4
San Mateo 4
Augusta 3
Brno 3
Dearborn 3
Guangzhou 3
Leawood 3
London 3
Nanchang 3
Norwalk 3
Ottawa 3
Redwood City 3
Verona 3
Aurora 2
Bangalore 2
Delianuova 2
Frankfurt am Main 2
Hong Kong 2
Indiana 2
Orange 2
Tianjin 2
Toronto 2
Ardabil 1
Bologna 1
Brisbane 1
Chicago 1
Chiswick 1
Clifton 1
Coyhaique 1
East Peoria 1
Edmonton 1
Falkenstein 1
Fuzhou 1
Gainesville 1
Hangzhou 1
Heredia 1
Kilburn 1
Kunming 1
Limerick 1
Monmouth Junction 1
Phnom Penh 1
Pisa 1
Porto Torres 1
Pune 1
Qingdao 1
Redmond 1
Secaucus 1
Southwark 1
Springfield 1
Stockholm 1
Zhengzhou 1
Totale 1.821
Nome #
[(pF)Phe4,Arg14,Lys15]N/OFQ-NH2 (UFP-102), a highly potent and selective agonist of the nociceptin/orphanin FQ receptor 168
Acute and chronic antiparkinsonian effects of the novel nociceptin/orphanin FQ receptor antagonist NiK-21273 in comparison with SB-612111 160
GluN2A and GluN2B NMDA receptor subunits differentially modulate striatal output pathways and contribute to levodopa-induced abnormal involuntary movements in dyskinetic rats 147
Pharmacological profile of nociceptin/orphanin FQ receptors regulating 5-hydroxytryptamine release in the mouse neocortex 130
Blockade of nociceptin/orphanin FQ receptor signaling in rat substantia nigra pars reticulata stimulates nigrostriatal dopaminergic transmission and motor behavior 129
In vivo evidence for a differential contribution of striatal and nigral D1 and D2 receptors to L-DOPA induced dyskinesia and the accompanying surge of nigral amino acid levels 128
Antagonism of metabotropic glutamate receptor type 5 attenuates L-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease 121
Blockade of nociceptin/orphanin FQ transmission attenuates symptoms and neurodegeneration associated with Parkinson's disease 117
Striatal Dopamine-NMDA receptor interactions in the modulation of glutamate release in the substantia nigra pars reticulata in vivo: opposite role for D1 and D2 receptors 116
Differential responsiveness of rat striatal nerve endings to the mitochondrial toxin 3-nitropropionic acid: implications for Huntington’s disease 116
Plasticity of glutamatergic control of striatal acetylcholine release in experimental parkinsonism: opposite changes at group-II metabotropic and NMDA receptors 115
Changes of glutamatergic control of striatal acetylcholine release in experimental parkinsonism 114
Pharmacological profiles of presynaptic nociceptin/orphanin FQ receptors modulating 5-hydroxytryptamine and noradrenaline release in the rat neocortex. 112
The selective D3 receptor antagonist, S33084, improves parkinsonian-like motor dysfunction but does not affect L-DOPA-induced dyskinesia in 6-hydroxydopamine hemi-lesioned rats 92
Differential role of striatal and nigral D1receptors in the expression of L-DOPA induced dyskinesia and its neurochemical correlates 91
Blockade of nociceptin/orphanin FQ transmission in rat substantia nigra reverses haloperidol-induced akinesia and normalizes nigral glutamate release 87
null 82
Nociceptin/orphanin FQ receptor antagonists riverse akinesia in rat parkinsonian models 71
Novel therapeutic strategies for treatment of motor abnormalities in Parkinson’s disease: focus on opioid receptors 70
L-DOPA-induced modulation of GABA and glutamate release in the substantia nigra pars reticulata and globus pallidus in a rat model of dyskinesia 69
Nociceptin/orphanin FQ receptor antagonists as a novel therapeutic approach to Parkinson’s disease: interaction with levodopa 66
Group-II metabotropic glutamate receptors negatively modulate NMDA transmission at striatal cholinergic terminals: role of P/Q-type high voltage activated Ca++ channels and endogenous dopamine 18
Totale 2.319
Categoria #
all - tutte 10.322
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 494
Totale 10.816


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020249 0 0 0 0 0 0 37 58 43 45 53 13
2020/2021301 29 29 15 34 16 36 10 33 8 31 43 17
2021/2022232 8 32 25 1 16 6 14 5 9 19 23 74
2022/2023248 24 27 14 25 49 34 6 17 40 1 8 3
2023/2024147 9 14 8 3 13 34 7 15 8 3 2 31
2024/2025238 12 10 45 19 61 88 3 0 0 0 0 0
Totale 2.319